Chunhai Charlie Hao
Co-Founder Degrome Therapeutics
Dr. Hao is a physician-scientist with over 30 years of experience in clinical neuropathology and laboratory research. He holds MD and PhD degrees and completed residency training in neuropathology. A Fellow of the Royal College of Physicians of Canada (FRCPC), Dr. Hao is a board-certified neuropathologist. His laboratory research focuses on targeted protein degradation, specifically the discovery of small-molecule glue degraders for disease-causing proteins. He co-founded HB Therapeutics, Inc., a company dedicated to developing molecular glue degraders targeting oncoprotein as first-in-class anticancer drugs. More recently, he co-founded Degrome Therapeutics, Inc., which is advancing molecular glue degraders for neurodegenerative diseases, with a current emphasis on targeting amyloid precursor protein (APP) in Alzheimer’s disease.
Seminars
- Enhancing targeted degradation of amyloid precursor protein (APP) by leveraging CAPRIN1-dependent lysosomal pathways to advance therapeutic strategies for Alzheimer’s disease
- Restoring neuronal stability through selective molecular glue modulation of APP processing, reducing amyloid accumulation and neurotoxicity
- Accelerating translational drug development using AI-assisted ligand and structure-based design to create blood-brain barrier–permeable APP degraders for Alzheimer’s therapy
